Toxicity Clinical Trial
Official title:
In Vivo Comparison of Genotoxic and Cytotoxic Effects of Different Brands of Toothpaste - Without and With Fluoride
Objectives. Toothpaste contains many potentially harmful ingredients, including some that can
lead to serious long-term health problems. Everyday use of oral health care products has
increased, highlighting the need for healthcare clinicians and consumers to be informed of
the potential benefits and risks associated with these products. The aim of this study is to
evaluate possible DNA damages to oral epithelial cells in participants exposed to toothpaste
containing fluoride as opposed to the effects of non-fluoride toothpaste.
Materials and Methods. Forty volunteers were selected among students of dental medicine and
assigned into two experimental groups. Each group used regular non-fluoride toothpaste for
initial two months, followed by the use of fluoride toothpaste of the same brand for the next
two months. The buccal epithelial cells were sampled at baseline and 30, 60, 90 and 120 days
after the beginning of the research. Chromosomal damages were analyzed by micronucleus assay.
The study included 40 participants, students of Dental Medicine at the School of Medicine, of
the University of Split. There were a total of 12 males and 28 females, aged between 20 and
26 (mean age 23.18 ± 1.48). Subjects were divided into two equal groups, depending on the
combination of the toothpaste used.
In the first group, Sensodyne Classic (GlaxoSmithKline, UK) and Sensodyne Fluor
(GlaxoSmithKline, UK) were the brands of toothpaste used, while in the second Plidenta 15
Seconds (Neva Ltd., Croatia) and Plidenta Sensitive (Neva Ltd., Croatia) (Table 1).
Participants have used toothpaste for four months. The first two months they used
non-fluoride toothpaste, after which, for the next two months, they used toothpaste
containing fluoride of the same manufacturer and similar composition. The tested kinds of
toothpaste were applied twice a day, in the morning and evening, for three minutes in the
amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene
such as mouthwash or topical fluoridation. A detailed medical and dental anamnesis were taken
from each participant. In a structured questionnaire, tailored to this study all participants
provided answers to questions related to demographic factors (age, gender), personal factors
(general health, a medication used, radiation exposure), lifestyle (smoking, alcohol
consumption) eating habits and oral hygiene habits. Individuals who smoked three or more
cigarettes a day for at least a year were considered as smokers. Those individuals who
consumed two or more alcohol units for three or more times a week were not included in the
study as well as patients with oral lesions, history of malignancy, and those with removable
and fixed prosthodontics, orthodontic appliances. The criterion for selecting participants
was to be completely healthy with no systemic disorders and diseases.
Sample collection Samples of buccal epithelial cells were collected from each participant
using the swab technique immediately prior to the use of tested toothpaste and 30, 60, 90 and
120 days after the beginning of the research (T0 - control prior to the use of tested
toothpaste, T1- 30 days after the beginning of the use of non-fluoride toothpaste, T2 - 60
days after the beginning of the use of non-fluoride toothpaste, T3 - 90 days after the
beginning of the study, using fluoride toothpaste for 30 days, T4 - 120 days after the
beginning of the study, using fluoride toothpaste for 60 days).
One hour prior the sampling, the participants were asked to abstain from smoking and
consuming any food and drinks. After rinsing of the oral cavity for three times with tepid
water in order to remove exfoliated cells, a swab was taken by gently brushing the buccal
mucosa bilaterally with a cytobrush (Cytobrush Plus, GmbH, Dietramszell-Linden, Germany) and
then the samples were applied to coded laboratory glass slides pre-warmed at 37 °C.
Micronucleus assay in buccal epithelial cells The cells applied on microscopic slides were
allowed to air-dry and then were fixed in methanol (80% v/v) at 4°C for 20 minutes. Staining
was carried out with 5% Giemsa solution for 10 minutes. Afterwards, the slides were rinsed
with aqua distillate and air-dried.
The analysis was done under a light microscope Olympus CX40 (Olympus, Tokyo, Japan) with a
400× magnification, and each micronucleus and other nuclear anomalies were additionally
verified under 1000× magnification. Two replicate slides were prepared for each subject, and
1000 epithelium cells per preparation were scored for each sampling time.
Statistical analysis Statistical analysis was done by using SPSS software package (IBM Corp.,
Armonk, NY, USA). By descriptive statistical analysis, the basic statistical parameters
(mean, standard error, and standard deviation, and relative standard deviation, median and
minimum and maximum values) were determined. The differences in the number of micronuclei and
other nuclear anomalies between different sampling times for each group and between the
groups of examinees were tested by ANOVA and Tukey's HSD post hoc test using a general linear
model procedure. General regression model (GRM) from linear/nonlinear modelling method was
used for the assessment of the influence of the predictor variables (age, gender, and
profession, use of medication, X-ray exposure, dietary habits, and lifestyle) onto dependent
variables (micronucleus, binucleated cells, broken eggs, nuclear buds, pyknosis, condensed
chromatin, karyolysis and karyorrhexis). The results of GRM are expressed in the form of
Pareto charts of t values. A significance level was set at 0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02273713 -
The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
|
Phase 1/Phase 2 | |
Terminated |
NCT00531076 -
Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02397434 -
Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer
|
N/A | |
Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02649491 -
Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy
|
N/A | |
Active, not recruiting |
NCT03975452 -
Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer
|
N/A | |
Terminated |
NCT00618917 -
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02760823 -
Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning
|
Phase 2 | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT00890448 -
Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate
|
N/A | |
Terminated |
NCT01760356 -
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
|
||
Recruiting |
NCT06044623 -
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
|
Phase 3 | |
Completed |
NCT01091766 -
Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine
|
Phase 4 | |
Completed |
NCT05277480 -
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
|
Phase 2 | |
Recruiting |
NCT03978949 -
Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)
|
Phase 3 | |
Completed |
NCT03491371 -
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
|
N/A | |
Completed |
NCT02143219 -
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02054741 -
Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT06087718 -
Feasibility of the Maastro Applicator in Rectal Cancer
|
N/A | |
Terminated |
NCT02512809 -
Isoflurane-induced Neuroinflammation in Children With Hydrocephalus
|
Phase 3 |